Origin

Pharma and AI companies lack large, high-quality patient-derived single-cell datasets to accurately evaluate how cancers respond to drugs and genetic therapies.

Origin builds and licenses a large patient-derived cancer single-cell dataset that measures responses to drugs and genetic medicines under DNA switch control.

Pharmaceutical companies and AI-driven life science organizations that license datasets for oncology drug discovery and development.